ArticleCell death & disease2025
MARCH2-mediated Lys63-linked polyubiquitination promotes metastasis by modulating the catalytic activity of TGF-β type I receptor.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The TGF-β signaling pathway is initiated when the type II receptor phosphorylates the type I receptor (ALK5) upon TGF-β binding. While E3 ubiquitin ligases regulate TGF-β receptor degradation, their role in modulating receptor catalytic activity via ubiquitination remains largely unexplored. Here, we demonstrate that the E3 ubiquitin ligase MARCH2 enhances ALK5 catalytic activity by conjugating K63-linked ubiquitin chains to lysines 342/343 (K342/343), primarily at endosomes following TGF-β-induced endocytosis. Mutations of ALK5 at K342/343 (K342/343R) abolish its catalytic activity for SMAD2 phosphorylation, leading to impaired TGF-β responses and reduced cell migration in A549 cells. In a mouse model, expression of the ALK5 K342/343 R mutant significantly decreases lung metastasis compared to wild-type ALK5. TCGA analysis further revealed a strong positive correlation between MARCH2 expression and TGF-β target gene expression. Collectively, these findings establish ALK5 ubiquitination at K342/343 by MARCH2 as a crucial regulatory mechanism for ALK5 catalytic activity, TGF-β signaling, and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.